Can-Fite BioPharma Ltd. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Can-Fite BioPharma Ltd. (CANF) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price of $87.31 per share as of 2025-12-31, per its 20-F filed 2026-03-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice · last filed 2026-03-26
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $87.31.
- 2025-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $0.03.
- 2024-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $0.03.
- 2024-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $0.04.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price |
|---|---|
| 2025-12-31 | $87.31 20-F · filed 2026-03-26 |
| 2025-06-30 | $0.03 6-K · filed 2025-08-28 |
| 2024-12-31 | $0.03 20-F · filed 2025-04-14 |
| 2024-06-30 | $0.04 6-K · filed 2024-08-29 |
| 2023-12-31 | $0.04 20-F · filed 2024-03-28 |
| 2023-06-30 | $0.08 6-K · filed 2023-08-31 |
| 2022-12-31 | $0.13 20-F · filed 2023-03-30 |